Literature DB >> 3263862

Inhibition of human hepatic and placental xenobiotic monooxygenases by imidazole antimycotics.

M Pasanen1, T Taskinen, M Iscan, E A Sotaniemi, M Kairaluoma, O Pelkonen.   

Abstract

Three imidazole antimycotic drugs, ketoconazole, clotrimazole and miconazole, were studied to characterize the inhibition of aryl hydrocarbon hydroxylase (AHH), 7-ethoxycoumarin O-deethylase (ECDE) and 7-ethoxyresorufin O-deethylase (ERDE) activities in human liver and placenta in vitro in comparison with liver enzymes from control, phenobarbital (PB) and 3-methylcholanthrene (MC) pretreated rats. All three compounds inhibited rat liver enzymes, although MC pretreatment seemed to lead to a resistance of inhibition relative to PB-treated and control animals. There were large differences in the extent of inhibition of human hepatic and placental activities. Furthermore, while the type of inhibition of the hepatic ERDE was competitive or mixed, that of the placental enzyme cannot be described in ordinary terms of inhibition kinetics. Ketoconazole and clotrimazole were relatively potent inhibitors of maternal cigarette smoking-induced placental ECDE activities (IC50 values from 0.5 microM to 5 microM), whereas much less inhibition of the placental AHH activity was obtained with ketoconazole and miconazole (IC50 values from 50 microM to 500 microM). In most cases, hepatic enzymes were less sensitive to antimycotics than placental activities. This was in contrast with results from rat enzyme studies, in which MC pretreatment seemed to decrease the inhibitory response.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263862     DOI: 10.1016/0006-2952(88)90067-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Disposition of azole antifungal agents. I. Nonlinearities in ketoconazole clearance and binding in rat liver.

Authors:  D Matthew; B Brennan; K Zomorodi; J B Houston
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

3.  Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies.

Authors:  K Zomorodi; J B Houston
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

4.  Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver.

Authors:  C M Ervine; J B Houston
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

5.  Disposition of azole antifungal agents. II. Hepatic binding and clearance of dichlorophenyl-bis-triazolylpropanol (DTP) in the rat.

Authors:  H L Bomont; M H Tarbit; M J Humphrey; J B Houston
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

6.  Characterization of the antiallergic drugs 3-[2-(2-phenylethyl) benzoimidazole-4-yl]-3-hydroxypropanoic acid and ethyl 3-hydroxy-3-[2-(2-phenylethyl)benzoimidazol-4-yl]propanoate as full aryl hydrocarbon receptor agonists.

Authors:  José Luis Morales; Jacek Krzeminski; Shantu Amin; Gary H Perdew
Journal:  Chem Res Toxicol       Date:  2008-01-08       Impact factor: 3.739

7.  In vitro forecasting of drugs which may interfere with the biotransformation of midazolam.

Authors:  M P Gascon; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.

Authors:  Y Ando; T Shimizu; K Nakamura; T Mushiroda; T Nakagawa; T Kodama; T Kamataki
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.